Lazaridis K, Tzartos S J. Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics[J]. Front Immunol, 2020,11:212.
[4]
Rivner M H, Pasnoor M, Dimachkie M M, et al. Muscle-Specific tyrosine kinase and myasthenia gravis owing to other antibodies[J]. Neurol Clin, 2018,36(2):293-310.
[5]
Panos S, Aditya K, Heiden J A, et al. Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis[J]. Ann NY Acad of Sci, 2018,1412(1):154-165.
[6]
Han J, Zhang J, Li M, et al. A novel MuSK cell-based myasthenia gravis diagnostic assay[J]. J Neuroimmunol, 2019,337:577076.
[7]
Yi J S, Guptill J T, Stathopoulos P, et al. B cells in the pathophysiology of myasthenia gravis[J]. Muscle Nerve, 2018,57(2):172-184.
[8]
Hurst R L, Gooch C L. Muscle-Specific receptor tyrosine kinase (MuSK) myasthenia gravis[J]. Curr Neurol Neurosci Rep, 2016,16(7):61.
Evoli A, Alboini P E, Damato V, et al. Myasthenia gravis with antibodies to MuSK: an update[J]. Ann N Y Acad Sci, 2018,1412(1):82-89.
[11]
Vincent A, Huda S, Cao M, et al. Serological and experimental studies in different forms of myasthenia gravis[J]. Ann N Y Acad Sci, 2018,1413(1):143-153.
Park K H, Waters P, Woodhall M, et al. Myasthenia gravis seronegative for acetylcholine receptor antibodies in south korea: autoantibody profiles and clinical features[J]. PLoS One, 2018,13(3): e0193723.
[15]
Martignago S, Fanin M, Albertini E, et al. Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR[J]. Neuropathol Appl Neurobiol, 2009,35(1):103-110.
[16]
Shin H Y, Park H J, Lee H E, et al. Clinical and Electrophysiologic Responses to Acetylcholinesterase Inhibitors in MuSK-Antibody-Positive Myasthenia Gravis: Evidence for Cholinergic Neuromuscular Hyperactivity[J]. J Clin Neurol, 2014,10(2):119-124.
[17]
Jian F, Wang H B, Chen N, et al. Observation of clinical and electrophysiological features in patients with distal myasthenia gravis[J]. Zhonghua Yi Xue Za Zhi, 2017,97(37):2894-2897.
Singh N, Goyal V. Rituximab as induction therapy in refractory myasthenia gravis: 18?month follow-up study[J]. J Neurol, 2019,266(7):1596-1600.
[25]
Einarsson J T, Evert M, Geborek P, et al. Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies[J]. Clin Rheumatol, 2017,36(12):2743-2750.
[26]
Grace R F, Shimano K A, Bhat R, et al. Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes[J]. Am J Hematol, 2019,94(7):741-750.
[27]
Dalakas M C. Immunotherapy in myasthenia gravis in the era of biologics[J]. Nat Rev Neurol, 2019,15(2):113-124.
[28]
Keung B, Robeson K R, DiCapua D B, et al. Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients[J]. J Neurol Neurosurg Psychiatry, 2013,84(12):1407-1409.
[29]
Topakian R, Zimprich F, Iglseder S, et al. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria[J]. J Neurol, 2019,266(3):699-706.
[30]
Clifford K M, Hobson-Webb L D, Benatar M, et al. Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis[J]. Muscle Nerve, 2019,59(4):404-410.
2020, Vol. 31 
